


PHARMACEUTICAL 2022



Cogent Biosciences Inc. Rank 188 of 475





PHARMACEUTICAL 2022



Cogent Biosciences Inc. Rank 188 of 475

The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 186% points. The greatest weakness of Cogent Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -46%, being 230% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	222,633
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,077
Liabilities, Non-Current	831
Other Assets	7,753
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,278
Property and Equipment	1,706
Research and Development	55,913
Revenues	0
Selling, General and Administrative Expense	19,638

Output Variable	Value in 1000 USD
Assets	232,092
Liabilities	17,908
Expenses	75,551
Stockholders Equity	214,184
Net Income	-72,273
Comprehensive Net Income	-72,273
Economic Capital Ratio	-46%